研究について【2022年】

英文原著論文　Original papers

発刊済のものはabstractまたは本文にリンクしてあります。
Published papers are linked to PubMed


Konishi T, Ogawa H, Najima Y, Hashimoto S, Kito S, Atsuta Y, Wada A, Adachi H, Konuma R, Kishida Y, Nagata A, Yamada Y, Kaito S, Mukae J, Marumo A, Noguchi Y, Shingai N, Toya T, Igarashi A, Shimizu H, Kobayashi T, Ohashi K, Doki N, Murofushi KN.

Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study.

Ann Med. 2022 Dec;54(1):2617-2626.



Marumo A, Omori I, Tara S, Otsuka Y, Konuma R, Adachi H, Wada A, Kishida Y, Konishi T, Nagata A, Yamada Y, Nagata R, Noguchi Y, Toya T, Igarashi A, Najima Y, Kobayashi T, Yamaguchi H, Inokuchi K, Sakamaki H, Ohashi K, Doki N.

Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less.

Asia Pac J Clin Oncol. 2022 Oct;18(5):e507-e514.



Nagata A, Otsuka Y, Konuma R, Adachi H, Wada A, Kishida Y, Konishi T, Yamada Y, Nagata R, Noguchi Y, Marumo A, Mukae J, Toya T, Igarashi A, Najima Y, Kobayashi T, Sakamaki H, Ohashi K, Doki N.

Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission.

Leuk Lymphoma. 2022 Sep 6:1-11.



Nishimura K, Konishi T, Ochi T, Watanabe R, Noda T, Fukumoto T, Miura N, Miyauchi Y, Kikugawa T, Takenaka K, Saika T.

CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma.

J Pers Med. 2022 May 28;12(6):888.



Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, Iwai M, Hashiguchi S, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Yoshihara S, Manabe M, Ichihara H, Mugitani A, Aoyama Y, Nakao T, Hirose A, Hino M, Ueda S, Takenaka K, Masuko T, Akashi K, Maruno T, Uchiyama S, Takamatsu S, Wada N, Morii E, Nagamori S, Motooka D, Kanai Y, Oji Y, Nakagawa T, Kijima N, Kishima H, Ikeda A, Ogino T, Shintani Y, Kubo T, Mihara E, Yusa K, Sugiyama H, Takagi J, Miyoshi E, Kumanogoh A, Hosen N.

Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.

Sci Transl Med. 2022 Feb 16;14(632):eaax7706.



Saito N, Yamauchi T, Kawano N, Ono R, Yoshida S, Miyamoto T, Kamimura T, Shultz LD, Saito Y, Takenaka K, Shimoda K, Harada M, Akashi K, Ishikawa F.

Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice.

Int J Hematol. 2022 Feb;115(2):198-207.



Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Edahiro Y, Akashi K, Matsumura I, Takenaka K, Komatsu N.

Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study.

Int J Hematol. 2022 Feb;115(2):208-221.



Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, Wada A, Kishida Y, Konishi T, Nagata A, Kaito S, Nagata R, Noguchi Y, Marumo A, Mukae J, Inamoto K, Toya T, Igarashi A, Kobayashi T, Sakamaki H, Ohashi K, Doki N.

Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI

Int J Hematol. 2022 Feb;115(2):244-254.



Jinnouchi F, Mori Y, Yoshimoto G, Yamauchi T, Nunomura T, Yurino A, Hayashi M, Yuda J, Shima T, Odawara J, Takashima S, Kamezaki K, Kato K, Miyamoto T, Akashi K, Takenaka K.

Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Int J Hematol. 2022 Jan;115(1):96-106.



Sumikawa S, Yakushijin Y, Aogi K, Yano T, Hiroki, Hashimoto, Tsukui C, Noguchi T, Shiraishi T, Horikawa Y, Yasuoka Y, Tanaka A, Hidaka N, Tanaka M.

Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).

Sci Rep. 2022 Jan 7;12(1):139.